Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant
-
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
-
A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020
-
Merck gains exclusive global development and commercialization rights; Debiopharm to receive €188 million upfront and up to €710 million in milestone, as well as royalty payments